Functional Tests and Surveys Used to Assess Nervous System Dysfunction in Patients with Fabry Disease – A Review
DOI:
https://doi.org/10.12775/QS.2025.37.57268Keywords
Fabry disease, autonomic nervous system, blood pressure, cold pressor testAbstract
Introduction and Purpose:
Fabry disease (FD) is a rare, X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A, leading to progressive multi-organ damage. Among the various complications, autonomic nervous system dysfunction has been suggested as a significant aspect of the disease’s pathophysiology. This review aims to evaluate functional tests and surveys used to assess nervous system dysfunction, focusing on the autonomic nervous system in FD patients.
State of Knowledge:
Fabry disease presents with classical and non-classical phenotypes, with early symptoms in males often involving pain, skin lesions, and gastrointestinal disturbances, progressing to more severe manifestations like heart failure and renal disease. The autonomic nervous system, which regulates various physiological processes, may be impaired in Fabry patients, potentially contributing to the disease’s symptoms. Functional tests such are frequently used to assess autonomic function. Studies on autonomic dysfunction in FD have provided mixed results, challenging the assumption that autonomic neuropathy plays a central role in disease progression.
Methods: A comprehensive search of references related to FDe and the autonomic nervous system was conducted on PubMed using the following search terms: “Fabry disease, autonomic nervous system, blood pressure, cold pressor test, vascular manifestations.”
Conclusions:
The findings of this review suggest that while autonomic dysfunction may be present in certain subsets of FD patients. Functional tests revealed limited evidence of widespread autonomic dysfunction. QSART showed reduced sweating responses in pain patients but no differences in non-pain patients. These results challenge the widely accepted notion that autonomic neuropathy is a major contributor to Fabry disease symptoms and emphasize the need for further research into the specific mechanisms underlying the disease's clinical manifestations.
References
1. Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of Anderson-Fabry Disease. Curr Pharm Des. 2020 Nov 27;26(40):5089–99.
2. Department of Nephrology, University of Medicine and Pharmacy of Craiova, Romania, Ilie-Robert D, Ştefan-George F, Clinic of Nephrology, Emergency County Hospital, Craiova, Romania. Fabry disease – current data and therapeutic approaches. Rom J Morphol Embryol. 2021 Oct 10;62(1):5–11.
3. Michaud M, Mauhin W, Belmatoug N, Bedreddine N, Garnotel R, Catros F, et al. Maladie de Fabry : quand y penser ? Rev Médecine Interne. 2021 Feb;42(2):110–9.
4. Slouma M, Ben Dhia S, Cheour E, Gharsallah I. Acroparesthesias: An Overview. Curr Rheumatol Rev. 2024 May;20(2):115–26.
5. Cortés-Saladelafont E, Fernández-Martín J, Ortolano S. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int J Mol Sci. 2023 Mar 9;24(6):5246.
6. Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023 Apr;60(4):391–6.
7. Zarate YA, Hopkin RJ. Fabry’s disease. The Lancet. 2008 Oct;372(9647):1427–35.
8. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*. Am J Hum Genet. 2006 Jul;79(1):31–40.
9. Averbuch T, White JA, Fine NM. Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies. Front Cardiovasc Med. 2023 Jun 2;10:1152568.
10. Bernardes TP, Foresto RD, Kirsztajn GM. Fabry disease: genetics, pathology, and treatment. Rev Assoc Médica Bras. 2020;66(suppl 1):s10–6.
11. Tuttolomondo A, Baglio I, Riolo R, Todaro F, Parrinello G, Miceli S, et al. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson–Fabry Disease. Int J Mol Sci. 2023 Dec 20;25(1):61.
12. Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011 Dec;11(1):61.
13. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, Dambrosia JM, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002 Nov;26(5):622–9.
14. Forstenpointner J, Sendel M, Moeller P, Reimer M, Canaan-Kühl S, Gaedeke J, et al. Bridging the Gap Between Vessels and Nerves in Fabry Disease. Front Neurosci. 2020 Jun 16;14:448.
15. Üçeyler N, Kahn AK, Kramer D, Zeller D, Casanova-Molla J, Wanner C, et al. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study. BMC Neurol. 2013 Dec;13(1):47.
16. Young TM, Asahina M, Nicotra A, Mathias CJ. Skin vasomotor reflex responses in two contrasting groups of autonomic failure: Multiple system atrophy and pure autonomic failure. J Neurol. 2006 Jul;253(7):846–50.
17. Wieling W, Van Brederode JFM, De Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: A data base for cardiac vagal neuropathy. Diabetologia. 1982 Mar;22(3):163–6.
18. Ducla‐Soares JL, Santos‐Bento M, Laranjo S, Andrade A, Ducla‐Soares E, Boto JP, et al. Wavelet analysis of autonomic outflow of normal subjects on head‐up tilt, cold pressor test, Valsalva manoeuvre and deep breathing. Exp Physiol. 2007 Jul;92(4):677–86.
19. Von Baeyer CL, Piira T, Chambers CT, Trapanotto M, Zeltzer LK. Guidelines for the cold pressor task as an experimental pain stimulus for use with children. J Pain. 2005 Apr;6(4):218–27.
20. Spinelli L, Giudice CA, Riccio E, Castaldo D, Pisani A, Trimarco B. Endothelial-mediated coronary flow reserve in patients with Anderson–Fabry disease. Int J Cardiol. 2014 Dec;177(3):1059–60.
21. Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: Importance of the functional integrity of the endothelium. J Am Coll Cardiol. 1989 Nov;14(5):1181–90.
22. Møller AT, Bach FW, Feldt‐Rasmussen U, Rasmussen ÅK, Hasholt L, Sommer C, et al. Autonomic skin responses in females with Fabry disease. J Peripher Nerv Syst. 2009 Sep;14(3):159–64.
23. Dincer MT, Ozcan SG, Ikitimur B, Kiykim E, Bakir A, Trabulus S, et al. Blood Pressure Variability in Fabry Disease Patients. Nephron. 2022;146(4):343–50.
24. Biegstraaten M, Van Schaik IN, Wieling W, Wijburg FA, Hollak CE. Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurol. 2010 Dec;10(1):38.
25. Kim HA, Yi HA, Hong JH, Lee H. Detailed Relationship Between the Pattern of Blood Pressure Change During the Valsalva Maneuver and the Degree of Orthostatic Hypotension During the Head-Up Tilt Test in Patients With Orthostatic Intolerance: A Retrospective Case–Control Study. Medicine (Baltimore). 2016 May;95(19):e3608.
26. Kim HA, Lee H, Park KJ, Lim JG. Autonomic dysfunction in patients with orthostatic dizziness: Validation of orthostatic grading scale and comparison of Valsalva maneuver and head-up tilt testing results. J Neurol Sci. 2013 Feb;325(1–2):61–6.
27. Rossi F, Svarstad E, Elsaid H, Binaggia A, Roggero L, Auricchio S, et al. Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease. High Blood Press Cardiovasc Prev. 2021 May;28(3):309–19.
28. Jain G, Warnock DG. Blood Pressure, Proteinuria and Nephropathy in Fabry Disease. Nephron Clin Pract. 2010 Nov 11;118(1):c43–8.
29. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O’Brien PC, Low PA. The Autonomic Symptom Profile: A new instrument to assess autonomic symptoms. Neurology. 1999 Feb;52(3):523–523.
30. Hilz MJ, Marthol H, Schwab S, Kolodny EH, Brys M, Stemper B. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J Hypertens. 2010 Jul;28(7):1438–48.
31. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003 Dec;28(6):703–10.
32. Stamerra CA, De Feo M, Castelli V, d’Angelo M, Cimini A, Grassi D, et al. Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson–Fabry disease. Eur J Hum Genet. 2021 Feb;29(2):218–24.
33. Hilz MJ, Koehn J, Kolodny EH, Brys M, Moeller S, Stemper B. Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy. J Hypertens. 2011 Dec;29(12):2387–94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Stanislaw Jesionek, Jakub Parys, Agnieszka Mikosińska, Martyna Kaźmierczak, Partycja Kałuziak, Marta Jajczak, Maciej Mossakowski, Aleksandra Witek, Mateusz Litwin, Justyna Jankowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 60
Number of citations: 0
